CEO INVESTOR CONFERENCE February 13-14, 2017 • The Waldorf Astoria New York

bio.org/CEO • #BIOCEO16

bio.org/CEO • #BIOCEO17 CEO INVESTOR CONFERENCE

Now in its 19th year, the BIO CEO & Investor Conference WHY ATTEND? is one of the largest investor • EXPERIENCE the largest, unbiased forum where institutional conferences focused on investors, industry analysts, and senior biotechnology executives shape the future investment landscape of the industry. established and emerging publicly traded and select • HEAR Washington’s perspective on how the Trump Administration will address ACA, CMS and PDUFA VI. private biotech companies. • EVALUATE fresh investment opportunities including compatible, complementary and competitive companies.

• LEARN about the hottest clinical developments and industry catalysts by attending the conference’s therapeutic workshops and business roundtables.

• ATTEND fireside chats with CEOs who will share their recent company successes, what keeps the C-suite up at night, and where the industry’s leading companies are headed in 2017.

• GAIN ACCESS to BIO’s One-on-One Partnering system for scouting potential investments and deal partners, optimizing your time at the event.

• HEAR presentations from more than 175 established public and private biotech companies and non-profit funding organizations, including many you won’t hear from at other investor conferences.

• GET THE PULSE of the current and proposed investment trends in biotechnology.

• NETWORK with peers, investors, and potential partners attending the conference and our exclusive receptions.

2 bio.org/CEO CEO INVESTOR CONFERENCE

2017 FIRESIDE CHAT SPEAKERS Fireside Chats feature candid discussions between biopharma executives, Wall Street analysts, and other high-level industry experts.

Hear about recent company Giovanni Caforio, MD Tony Coles, MD Chief Executive Officer, Chairman and Chief successes, what keeps the Bristol-Myers Squibb Executive Officer, C-suite up at night, and Yumanity Therapeutics where the industry’s leading companies are headed in 2017.

Jeffrey D. Marrazzo J. Joseph Kim, PhD Co-Founder and Chief President and Chief Executive Officer, Executive Officer, Spark Therapeutics Inovio Pharmaceuticals

Lynn Seely, MD Chief Executive Officer, Myovant Sciences

#BIOCEO17 3 2017 AGENDA

APPLYING MICROBIOME RESEARCH SPEAKERS Joseph Pearlberg, MD, Vice President Clinical TO THERAPEUTICS Development, Infinity Pharmaceuticals, Inc. Monday • February 13, 2017 • 9:00 am – 9:55 am Jeffrey Wolf, Chief Executive Officer, Heat Biologics New discoveries are finding links that extend significantly Anton Xavier, Senior Scientist, Inc. beyond the gut microbiome and intestinal disorders into a range of bodily systems including the immune and nervous systems. Jerome Zeldis, MD, PhD, Chief Medical Officer Major biopharma companies have engaged in significant deals and President of Clinical Development, Sorrento that envision treatments to commercialize from this research Therapeutics and leading companies are pushing forward on clinical trials. This session will outline the microbiome influenced therapies NEXT GENERATION PAIN CONTROL: most likely to create major effects for patients. BEYOND OPIOIDS MODERATOR: C. Simone Fishburn, PhD, Editor, Monday • February 13, 2017 • 1:30 pm – 2:25 pm BioCentury Innovations The scourge of rising addiction and heroin overdoses has SPEAKERS Pierre Belichard, PharmD, PhD, Chief been associated with the growth in usage of important, opioid- Executive Officer, Enterome based, prescription pain treatments. New approaches to pain Mark Bodmer, PhD, Chief Scientific Officer, control are looking at different biological mechanisms and Evelo Biosciences methodologies for improving patients’ lives with lower risks of ill effects or addiction. This session will speak with experts Aoife M. Brennan, MD, Chief Medical Officer, Synlogic developing therapeutic innovations that do not rely on opioid- based drugs and can provide doctors additional alternatives for Nick Conley, PhD, Board of Directors, helping patients. Co-founder & Chief Executive Officer, EpiBiome Jeffrey Riley, Chief Executive Officer, President MODERATOR: Corey Davis, PhD, Managing Director, Senior and Director, Synthetic Biologics Healthcare Analyst, H.C. Wainwright & Co., LLC Nikola Trbovic, PhD, Director R&D Technology SPEAKERS Gail Cawkwell, MD, Chief Medical Officer, Strategy, Worldwide Research & Development, L.P. Pfizer Inc. Derek Chalmers, PhD, DSc, Chief Executive Officer, President, and Director, Cara Therapeutics FIRESIDE CHAT WITH J. JOSEPH KIM, PHD Russell Herndon, President and Chief President and Chief Executive Officer, Executive Officer, Hydra Biosciences Inovio Pharmaceuticals Jeffrey B. Kindler, Chief Executive Officer, Monday • February 13, 2017 • 10:00 am – 10:55 am Centrexion Therapeutics MODERATOR Phyllis A. Arthur, Managing Director, Infectious Diseases and Diagnostics Policy, Biotechnology FIRESIDE CHAT WITH TONY COLES, MD Innovation Organization Chairman and Chief Executive Officer, Yumanity Therapeutics Monday • February 13, 2017 • 2:30 pm – 3:25 pm CAR-T, TILS, AND BISPECIFICS: IMMUNO- MODERATOR Ian Woo, Managing Director, Lazard ONCOLOGY CHALLENGES AND OPPORTUNITIES Monday • February 13, 2017 • 11:00 am – 11:55 am The maturation of new cancer treatment technologies has IPOS AND BEYOND: TAPPING INTO THE PUBLIC produced a mix of highly positive patient outcomes and some MARKET’S CAPITAL serious clinical holds, while investments for manufacturing and Monday • February 13, 2017 • 3:30 pm – 4:25 pm commercialization continue to accelerate. This session will dive As biotech IPO activity has cooled from its 2015 peak, into the assumptions underlying the most aggressive approaches companies are more deliberately weighing reverse mergers and the ways of reducing the risks of failure along the way to and other alternatives to benefiting from the capital in public delivering immuno-oncology’s promise to patients broadly. markets. With post-election market uncertainty, does the IPO MODERATOR: Michael King, Managing Director and Senior market for 2017 seek to rise, fall, or stay level? What markers Research Analyst, JMP Securities should CEOs watch for to gauge their timing and choices?

4 bio.org/CEO CEO INVESTOR CONFERENCE

This session will feature experienced voices for explaining the EMBEDDING DIVERSITY INTO BOARD AND practical techniques for getting into public markets and what EXECUTIVE TEAM RECRUITMENT investors are expecting to see in order to win their support. Tuesday • February 14, 2017 • 10:00 am – 10:55 am MODERATOR Stephen B. Thau, Partner, Morrison & The biopharma industry has seen enormous growth in recent Foerster LLP years of the number of start-ups and IPOs, with hundreds of SPEAKERS James Cappuccio, Managing Director, new executive team and board member positions being filled. Investment Banking, H.C. Wainwright & Co., LLC However, the inclusion of underrepresented groups in these Brian Hagerty, Senior Director, Head of influential positions has failed to keep pace with the growth of Healthcare Capital Markets, New York biopharma companies and too often the decision-makers fail Stock Exchange to reflect the employee bases they lead or patient populations Douglas E. Onsi, Chief Financial Officer, they serve. This session will focus on practical approaches and Leap Therapeutics, Inc. successful examples to improve the diversity of leadership recruitment efforts and better align organizations with the full Sapna Srivastava, PhD, former Chief Financial measure of talented people available. Officer and Chief Strategy Officer, Intellia Therapeutics MODERATOR Julie L. Gerberding, MD, MPH, Executive Vice Nassim Usman, PhD, President and Chief President & Chief Patient Officer, Strategic Executive Officer, Catalyst Biosciences Communications, Global Public Policy and Population Health, Merck FIRESIDE CHAT WITH LYNN SEELY, MD SPEAKERS Colleen Cuffaro, PhD, Principal, Canaan President and Chief Executive Officer, Myovant Sciences Partners Monday • February 13, 2017 • 4:30 pm – 5:25 pm Faith L. Charles, Partner, Chair, Life Sciences, Thompson Hine LLP/ Chair, Women in Bio— MODERATOR K.C. Stone, Managing Director, Head of Metro New York Healthcare Investment Banking BTIG , Linda S. Grais, MD, President and Chief Executive Officer, Ocera Therapeutics, Inc. LIVING WITH BIOSIMILARS: STRATEGY Paul J. Hastings, Chairman and Chief Executive FORMULATION AND LESSONS FROM Officer, OncoMed Pharmaceuticals OTHER MARKETS Stephen M. Ritoch, Chairman of the Board and Chief Executive Officer, Blaise GroupFaith Tuesday • February 14, 2017 • 9:00 am – 9:55 am As biosimilar medicine options begin to roll-out in the United FIRESIDE CHAT WITH JEFFREY D. MARRAZZO, States, the regulatory and legal uncertainties are also starting Co-Founder and Chief Executive Officer, Spark to shrink below the market adoption uncertainties. As some Therapeutics innovator companies also pursue biosimilar development, and others seek to compete, there are opportunities to learn from Tuesday • February 14, 2017 • 11:00 am – 11:55 am jurisdictions that have allowed biosimilar medicines for longer MODERATOR Erin McCallister, Senior Editor, BioCentury periods, such as Japan and Europe regarding the reactions Publications of doctors and payers. This session will feature executives from innovator companies explaining how they evaluate biosimilars within their pipelines, plus those with expertise on POLICY OUTLOOK—ACA, CMS, PDUFA VI AND understanding the economic effects seen when biosimilars THE TRUMP ADMINISTRATION launch within a market. Tuesday • February 14, 2017 • 12:30 pm – 1:25 pm MODERATOR Elizabeth Krutoholow, Senior Analyst, From a healthcare policy point of view, 2017 has the potential Bloomberg Intelligence of being the most dramatic since the initial introduction of SPEAKERS Jennifer Alltoft, Head of Global Biosimilars, the Affordable Care Act. The new Trump Administration has Pfizer, Inc. suggested an interest in making wholesale changes in how Patrick K. Lucy, Interim Chief Executive Officer, medicines are regulated and paid for by the U.S. government. Pfenex PDUFA will expire later this year if its planned replacement is not passed in a timely fashion, greatly complicating companies’ drug development strategies and budgets. This session will share the latest details on what policies the Trump Administration and Congress are pursuing that would support or upend the assumptions that biopharma executives and investors have built into their financial models.

#BIOCEO17 5 MODERATOR Susan Peschin, MHS, President and Chief MODERATOR Wade Ackerman, Partner, Covington & Executive Officer, Alliance for Aging Research Burling LLP SPEAKERS Alex M. Azar II, Chairman, Seraphim Strategies, SPEAKERS Jeff Allen, PhD, President & Chief Executive LLC; former President, Lilly USA, LLC Officer, Friends of Cancer Research (2012-2017); former Deputy Secretary, U.S. Gregory W. Daniel, PhD, MPH, RPh, Deputy Department of Health and Human Services Director, Duke-Margolis Center for Health Policy (2005-2007) Steven Kaminsky, PhD, Chief Science Officer, Jeanne Haggerty, Senior Vice President, Rettsyndrome.org Federal Government Relations, Biotechnology Christopher U. Missling, PhD, President and Innovation Organization (BIO) Chief Executive Officer, Anavex Life Sciences Jonathan Leff, Partner, Deerfield Management; Corp. Chairman, Deerfield Institute Raghuram Selvaraju, PhD, Managing Director, Brian Rye, Senior Healthcare Policy Analyst, Senior Healthcare Analyst, Rodman & Renshaw, Bloomberg Intelligence a unit of H.C. Wainwright & Co., LLC CRAFTING NEW APPROACHES TO VALUE- BASED THERAPY PAYMENT MODELS: FIRESIDE CHAT WITH GIOVANNI CAFORIO, MD STARTING WITH GENE THERAPIES Chief Executive Officer, Bristol-Myers Squibb Tuesday • February 14, 2017 • 3:30 pm – 4:25 pm Tuesday • February 14, 2017 • 1:30 pm – 2:25 pm MODERATOR Stephen Sands, Vice Chairman Investment Both innovator companies and payers of medicines have Banking and Chairman Global Healthcare expressed a willingness to look beyond the “fee per pill” Group, Lazard model to attributing value to the effects on patients’ health instead. The challenge of reimbursing for curative therapies versus lifelong treatments of chronic conditions presents a MARKET OUTLOOK—POST-INAUGURATION special challenge, but one that may shine a light on value- SCENARIOS FOR M&A based approaches generally. This session will explore with the innovators making progress on gene therapies how they Tuesday • February 14, 2017 • 4:30 pm – 5:30 pm are envisioning the reimbursement model in ways that all While the past year has seen a fading in the IPO market, the stakeholders might appreciate, including doctors’, patients’, and volume of deal flow and valuations for M&A remain high. Many payers’ perspectives. of the largest industry members have strong cash positions, MODERATOR Ted Haack, Owner, Managing Partner, and most analysts continue to expect pipeline enhancement via Haack & Associates acquisition. As political forecasts suggest high potential for tax reform and other changes in how international deals might be SPEAKERS John Glasspool, (formerly Executive Vice reviewed, there are multiple ways 2017 could be a great year or a President, Head of Corporate Strategy and terrible year for biopharma M&A. This session will talk through the Customer Operations at Baxalta US, Shire) likely and extreme scenarios, as well as provide insight on what Roger Longman, Chief Executive Officer, Real signs to watch for from Washington and Wall St. along the way. Endpoints MODERATOR Asthika Goonewardene, Senior Biotech Sandy Macrae, MB, ChB, PhD, President and Analyst, Bloomberg Intelligence Chief Executive Officer, Sangamo Biosciences, Inc. SPEAKERS Adam H. Golden, Partner, Head of Corporate Practice Group—New York, Hogan Lovells DESIGNING CLINICAL TRIALS IN A 21ST Ellen Lubman, Vice President, External Science CENTURY CURES PARADIGM & Innovation, PLC Tuesday • February 14, 2017 • 2:30 pm – 3:25 pm Michael A. Margolis, RPh, Head of Healthcare Investment Banking, ROTH Capital Partners The passage by Congress of the 21st Century Cures Act in late 2016 has opened up new opportunities and expectations for the Dennis J. Purcell, Founder and Senior Advisor, design of clinical trials that the FDA will consider for regulatory Aisling Capital review. Real world evidence and the stronger inclusion of  Matthew Roden, PhD, Vice President and patient perspectives on endpoints are two examples of the Head of Strategic Corporate Development, shifts that will impact therapy development. This session Bristol-Myers Squibb will explain the advantages and complications that drug developers and investors should be aware of as the Cures Act CLOSING RECEPTION AND CHAMPAGNE TOAST gets implemented. Tuesday • February 14, 2017 • 5:30 pm – 6:30 pm

6 bio.org/CEO CEO INVESTOR CONFERENCE

2017 PRESENTING COMPANIES The 2017 BIO CEO & Investor Conference will better accommodate the growing diversity of investors and companies. While the majority of presenting companies at this event are publicly traded, with about half trading with market capitalizations above $100M, this meeting will once again feature a unique track of more than 30 high-caliber and established private company presentations.

CARDIOVASCULAR Sigmoid Pharma Limited The Leukemia & Lymphoma Society TG Therapeutics (NASDAQ: TGTX) Angionetics Inc. Synthetic Biologics, Inc (NYSE: SYN Tourette Association of America, Inc. Vascular Biogenics LTD (NASDAQ: Capricor Therapeutics, Inc. (NASDAQ: GENE/CEN THERAPY ONCOLOGY VBLT) CAPR) Argos Therapeutics, Inc (NASDAQ: 2X Oncology, Inc Vaxil Bio Ltd. (TSX-V: VXL) Espero Pharmaceuticals, Inc. ARGS) 4SC AG (FWB: VSC) Verastem, Inc. (NASDAQ: VSTM) Karos Pharmaceuticals Brainstorm cell Therapeutics Actinium Pharmaceuticals, Inc (NYSE WILEX AG (FWB: WL6) ORIG3N, Inc. (NASDAQ: BCLI) MKT: ATNM) Zenith Epigenetics Ltd. Resverlogix Corp. (TSX: RVX) Caladrius Biosciences, Inc. (NASDAQ: Aeterna Zentaris (NASDAQ: AEZS) OPTHALMOLOGY CNS/NEUROLOGICAL CLBS) Apexian Pharmaceuticals Inotek Pharmaceuticals Corporation AcelRx Pharmaceuticals (NASDAQ: Cellular Biomedicine Group (NASDAQ: Aveo Oncology (NASDAQ: AVEO) (NASDAQ: ITEK) ACRX) CBMG) BioLineRx Ltd. (NASDAQ, TASE: BLRX) Ocugen, Inc. Alcobra (NASDAQ: ADHD) Editas Medicine (NASDAQ: EDIT) Bio-Path Holdings, Inc. (NASDAQ: Ocular Therapeutix, Inc. (NASDAQ: Axsome Therapeutics, Inc. (NASDAQ: Heat Biologics (NASDAQ: HTBX) BPTH) OCUL) AXSM) LogicBio Therapeutics Inc Calithera Biosciences (NASDAQ: ThromboGenics NV (Euronext: THR.BR Flex Pharma, Inc. (NASDAQ: FLKS) Oxford BioMedica Ltd (LSE: OXB) CALA) ORPHAN/RARE DISEASE InVivo Therapeutics Corporation TxCell SA (Euronext: TXCL.PA Cellectar Biosciences, Inc. (NASDAQ: Albireo Pharma Inc (NASDAQ: ALBO) (NASDAQ: NVIV) IMMUNOLOGY CLRB) Arcturus Therapeutics Neuralstem, Inc. (NASDAQ: CUR) BioNTech AG ConcentRx, Inc. Bellerophon Therapeutics (NASDAQ: NeuroRx, Inc. Enterome CTI BioPharma Corp. (NASDAQ: CTIC) BLPH) Neurotrope Bioscience (OTC: NTRP) OSE Immunotherapeutics (Euronext: Cue Biopharma Inc Catalyst Biosciences (NASDAQ: CBIO) Newron Pharmaceuticals SPA (SIX: OSE) Cyclacel Pharmaceuticals, Inc. Eiger BioPharmaceuticals, Inc NWRN) Sorrento Therapeutics (NASDAQ: (NASDAQ: CYCC, CYCCP) (NASDAQ: EIGR) ORYZON (BME: ORY) SRNE CytRx Corporation (NASDAQ: CYTR) EryDel SpA PHARNEXT (Alternext: ALPHA) Eleven Biotherapeutics (NASDAQ: InMed Pharmaceuticals (CSE: IN, Probiodrug AG (Euronext: PBD) INFECTIOUS DISEASES EBIO) Altimmune, Inc. OTCQB: IMLFF) RaNA Therapeutics epiSCI ProMetic Life Sciences (TSX: PLI) Serina Therapeutics, Inc. American Gene Technologies ESSA Pharma Inc. (NASDAQ: EPIX, International Inc. Spotlight Innovation Inc. (OTCQB: Tonix Pharmaceuticals Holding Corp. TSX: EPI) STLT) (NASDAQ: TNXP) AmpliPhi Biosciences Corp (NYSE Fennec Pharmaceuticals (TSX: FRX) MKT: APHB) Summit Therapeutics (NASDAQ: DERMATOLOGY Gradalis, Inc. SMMT) ContraVir Pharmaceuticals, Inc. Gritstone Oncology, Inc Exicure Inc. (NASDAQ: CTRV) OTHER Foamix Pharmaceuticals (NASDAQ: Helix BioPharma Corp. (TSX: HBP) EpiBiome Immunicum AB (NASDAQ First North 22nd Century (NYSE: XXII) FOMX) Rebiotix, Inc. Akebia Therapeutics, Inc. (NASDAQ: Realm Therapeutics, Inc. (AIM: RLM) Premier: IMMU) Spring Bank Pharmaceuticals, Inc. Immunovaccine (TSX: IMV, OTCQX: AKBA) Sonoma Pharmaceuticals, Inc. (NASDAQ: SBPH) Capnia, Inc. (NASDAQ: CAPN) (NASDAQ: SNOA) IMMVF) Vical Incorporated (NASDAQ: VICL) Infinity Pharmaceuticals, Inc. (NASDAQ: PAIN MANAGEMENT DIAGNOSTICS Noveome Biotherapeutics INFI) Centrexion Therapeutics Baebies, Inc. INFLAMMATION iTeos Therapeutics SA KemPharm, Inc. (NASDAQ: KMPH) Biocept, Inc. (NASDAQ: BIOC) Noveome Biotherapeutics Leap Therapeutics, Inc. (NASDAQ GS: Proove Biosciences Inc. Chembio Diagnostics, Inc. (NASDAQ: MEDICAL DEVICES LPTX) Relmada Therapeutics, Inc. (OTCQB: CEMI) MabVax Therapeutics Holdings, Inc. RLMD) Curetis N.V. (Euronext: CURE) Arch Therapeutics, Inc. (OTC: ARTH) CytoSorbents (NASDAQ: CTSO) (NASDAQ: MBVX) PLATFORM FOR THERAPEUTICS Epinex Diagnostics, Inc. Mateon Therapeutics (OTCMKTS: Exactus, Inc. (OTCQB: EXDI) METABOLIC DISEASE Dimerix Ltd (ASX: DXB) MATN) RXi Pharmaceuticals Corporation Exosome Diagnostics, Inc. AptamiR Therapeutics, Inc. MetaStat, Inc. (OTCBB: MTST) Interpace Diagnostics Group Inc. CohBar, Inc. (OTC: CBWR) (NASDAQ: RXII) Nanobiotix (Euronext: NANO) SmartZyme Biopharma Ltd. (NASDAQ: IDXG) Cymabay Therapeutics (NASDAQ: Novocure Limited (NASDAQ: NVCR) ITUS Corporation (NASDAQ: ITUS) CBAY) OncoMed Pharmaceuticals, Inc. REGENERATIVE MEDICINE LexaGene Holdings Inc. (TSX: LXG.V) Orexigen Therapeutics, Inc. (NASDAQ: (NASDAQ: OMED) BioTime, Inc. (NYSE MKT: BTX) Oncocyte (NYSE MKT: OCX) OREX) Onconova Therapeutics, Inc. REPRODUCTIVE/SEXUAL HEALTH DRUG DELIVERY Synlogic (NASDAQ: ONTX) Agile Therapeutics, Inc (NASDAQ: Apricus Biosciences, Inc. (NASDAQ: Viking Therapeutics, Inc. (NASDAQ: OncoSec Medical Incorporated AGRX) APRI) VKTX) (NASDAQ: ONCS) Palatin Technologies, Inc. Corium International, Inc. (NASDAQ: MULTILINE GLOBAL BIOPHARMA Opsona Therapeutics Ltd. (NYSE MKT: PTN) CORI) NOIGEL, LLC Pieris Pharmaceuticals (NASDAQ: RESPIRATORY Oramed Pharmaceuticals (NASDAQ: MULTIPLE THERAPEUTICS PIRS) Aradigm Corporation (NASDAQ: ARDM) ORMP) Citius Pharmaceuticals, Inc. (OTCQB: Progenics Pharmaceuticals,Inc. RespireRx Pharmaceuticals Inc. pSivida Corp (NASDAQ: PSDV) CTXR) (NASDAQ: PGNX) (OTCQB: RSPI) GASTROINTESTINAL Fortress Biotech, Inc. (NASDAQ: FBIO) Salarius Pharmaceuticals Scancell Holdings plc (LSE: SCLP.L) TOOLS/DRUG DEVELOPMENT Atlantic Healthcare plc Mount Tam Biotechnologies (OTC: SUPPORT TECHNOLOGY Conatus Pharmaceuticals Inc. MNTM) SciClone Pharmaceuticals Inc (NASDAQ: SCLN) IonField Holdings LLC, (NASDAQ: CNAT) Symic Bio, Inc. dba IonField Systems Galectin Therapeutics (NASDAQ: TiGenix NV (Euronext: TIG) Sunesis Pharmaceuticals (NASDAQ: SNSS) Vium Inc. GALT) NON-PROFIT/ADVOCACY Innovate Biopharmaceuticals, Inc. Sutro Biopharma Inc. VACCINES ORGANIZATION Syros Pharmaceuticals (NASDAQ: JN Medical Corp. RedHill Biopharma Ltd. (NASDAQ, Jeffrey Modell Foundation TASE: RDHL) SYRS) Universal Stabilization Technologies, Inc. Muscular Dystrophy Association Tarveda Therapeutics Vaxess Technologies

#BIOCEO17 7 2017 PARTICIPATING INVESTORS

INVESTORS Deca Ventures, LLC 5AM Ventures DeepStream Global Management A C Binder Corp Deerfield Management AbbVie Inc. Delphi Ventures Aceras Delwar Capital Management LLC Aceras Life Sciences Discover Fund Aceras Partners Dolphin Asset Management ACS Investment Partners Domain Associates ACT Capital Management Dynamk Capital Acuris Partners E Squared Capital Aegis Capital Eagle Asset Management Aisling Capital LLC Easton Capital Akemi Capital Edgewood Management LLC ALEPH CAPITAL EGB Advisors PR LLC Alignment Ventures, LLC Eleven Biotherapeutics Amzak Health Emerald Advisers Anson Funds Enso Ventures Arch Venture Partners ESC Advisors Arcus Ventures Eversept Partners Ariel Investments excelyrate Capital Aristar Capital Faridan Asahi Kasei America, Inc. FBR & Co. INVESTOR Ashford Capital Management FC Capital Management Aspire Capital Partners Federated Kaufmann Fund Astellas Venture Management LLC First Island Capital REGISTRATION ATEL Ventures Five Prime Advisors LLC Athena Bio Ventures Fletcher Spaght Ventures UP MORE THAN Atheneos Capital FMB Research Inc. Athyrium Capital Management Fosun Pharma Group-Wanbang Atlantic Capital Group Fountain Healthcare Partners Atlas Venture F-Prime Capital Partners Auxol Capital Franklin Templeton AWM Investment Co FundRx 30% Baird Capital GCF Family Office Bank of America/Merrill Lynch GC Finance Barclays Genesys Capital Partners OVER 2016. Barracuda Finance LLC GenScript Bearing Circle Capital Global Asset Advisors BioMed Ventures GMX Capital Partners Biondo Investment Advisors Goldwater Biotech Investment Group Good Health Capital BioVenture Partners Gradus/RSJ Life Sciences Bishop Capital Management Griffin Securities BMO Capital Hayfin Capital Management Brean Capital H.C. Wainwright & Co. BridegBio HealthCare Royalty Partners Brio Capital Healthcare Value Capital, LLC BTIG Helix Management, Inc Cabot Capital Group Hercules Capital CAM Capital HI Investors Capital Canaccord Genuity H.I.G. Capital Cantor Fitzgerald Horizon Technology Finance Capital Family Office Horton Point LLC Capital Midwest Fund Hudson Bay Capital Cato BioVentures Humanwell Healthcare Group Cedrus Investments Ignite Capital Chardan Capital Markets Illumina Ventures Church Pension Fund Innoviva, Inc. Cowen International Finance Corporation Crede Capital Group Inventis Investment Holdings (China) Ltd Crosby Advisors iNVENTRAM INC. Crown Point Group IRC Securities/Strategy Signal Dabar Investment Associates Iron Wolf Advisors Daniloff Capital Janney Montgomery Scott Data Collective Jefferies

8 bio.org/CEO CEO INVESTOR CONFERENCE

JEG Capital Partners LLC NovaQuest Capital Stadnyk and Partners Family Office JH Darbie & Co Novatio Ventures Stanphyl Capital Jina Ventures Inc. Novo Nordisk SternAegis Ventures JMP Securities NSIP LLC Stifel Johnson & Johnson Innovation - JJDC Inc NYS Innovation Venture Capital Fund SunTrust Robinson Humphrey Johnston Associates Oak Ridge Investments LLC Surveyor Capital (Citadel LLC) JonesTrading Oberland Capital SV Life Sciences Managers LLP JP Morgan Securities Oechsle International Advisors Symphony Capital LLC Kalka Fund Olayan America Corp Syno Capital Katalyst Securities LLC Opaleye TaiAn Technologies/Eminent VC Katz Associates Oppenheimer & Co Tang Capital Management KCM Opus Point Partners Tanaka Capital Management KESA Partners OrbiMed The Astrologers Fund, Inc L1 Capital Global Orchard View Capital Advisors LP The HF Group, LLC Ladenburg Thalmann & Co. Oxford Finance TriPoint Global Equities Laidlaw & Company Palo Alto Investors Tryphon Capital Advisors LF Advisors LLC Pappas Ventures TS Family of Funds Leerink PARK AVE CAPITAL MGMT INTL. Turret Capital Mangement Leonite Capital Parkfield Funding, LLC V2M Capital LifeScience EquityPartners, LLC Parkville Advisors Valquest Capital Management LifeTech Capital Park York LLC Vector Capital Ltd Lincoln Financial Adisors Peter B. Cannell & Co. Vector Resource Funds Lincoln Park Capital Petrus Capital Holdings Versant Ventures Little gem life sciences fund Pfizer Inc Viriathus Holdings LLX Livingston LLC Pipeline Capital Virtus Inspire Ventures Loeb Partners Piper Jaffray Vista Point Capital Loncar Investments Portola Captial Partners WallachBeth Capital Longitude Capital Prevail Partners LLC WBB Securities LLC LPL Financial Princeton BioPharma Capital Partners, Wellington Financial LSWORKS LLC WestPark Capital Madison Square Capital LLC Princeton Portfolio Strategies Group, LLC William Blair Magid Family Office Prism Biomedical Research Wolf Capital Management Magna Qilu BioVentures Fund Wolfswood Partners Marathon Asset Management QVT Financial Xeraya Capital Maxim Group Rainbow Bridge Advisors Mayfair Capital Partners LLC Raymond James Maz Capital Advisors LLC RBC Capital Markets Medex Capital Relativity Healthcare Partners Mediqventures Remiges Ventures Merck Revach Fund LP Mid Atlantic Bio Angels Ridgeback Capital Management Milestone Capital Roosevelt Investments Morgan Stanley ROTH Capital Partners Morgens, Waterfall, Vintiaidus & Company, Ruddigore Partners Inc. S&P Capital IQ Mossrock Capital, LLC Sachs Investment Group Mountain Brook Capital Santen Inc Mount Sinai Investment Fund SBIC Program MP Healthcare Venture SBP Management M&T Global Partners SC Fundamental, LLC MTS Health Investors Schroder Investment Management MVM Life Science Partners Seaside88 MVP Capital Partners Second Line Capital National Securities Corporation Sector Asset Management NEA Serrado Capital Needham & Co. Silicon Valley Bank New Frontier Capital, LP Silverarc Capital, LLC Nexus LSP Silverarrowpartners NJ Investment Division SimRx advisors Noble Equity Sio Capital Management Noble Life Science Partners Skolkovo Biofund Nomura Instinet Slater Technology Fund Nomura Securities International Sofinnova Ventures Nordcon Capital Solar Capital Partners Norgine Ventures Source Capital Group

#BIOCEO17 9 BIO ONE-ON-ONE PARTNERING MEETINGS SCHEDULED MEETINGS UP 20% Using the system, companies are able to: BIO’s One-on-One Partnering™ m Pre-schedule 30-minute private 1x1 meetings system is the interactive m Source potential collaborations and funding environment that allows opportunities with an international audience you to increase your productivity, discover m Communicate directly with prospective new investment and investors and C-level executives in biotech licensing opportunities, and pharma and expand your business potential worldwide. m Search company and investor profiles for potential business partnerships

AUDIENCE DEMOGRAPHICS Job Profile: Attendees: 1,400+ 86% BIO One-on-One 86% of attendees Partnering Meetings: 2,500+ are VP or C-Level 86% Registered Investors: 650 4% 10% 76% 10% Company Presentations: 190 Other Director C-level VP Expert Speakers: 58

Companies Profile: Breakdown by Therapeutic Focus: Diagnostics: 2% Infectious Diseases: 2% 82% of all companies Gastrointestinal: 3% Platform Discovery: 2% attending are biopharma 82% Cardiovascular: 3%

Regenerative Medicine: 3% Oncology: 29% Multiple: 4%

Breakdown by Market Cap: Ophthalmology: 4% $250M-500M: 6% $500M: 4% Metabolic Diseases: 4%

Devices & Drug Delivery: 4% $50M-100M: 22% CNS: 13% < $50M: 36% Autoimmune Inflammation:7%

Orphan/Rare Diseases: 10% Other: 10% $100M-250M: 32%

10#BIOCEO17 bio.org/CEO10 CEO INVESTOR CONFERENCE

SPONSORS LOCAL CO-HOST REGIONAL PARTNERS

SUPPORTING BANK SPONSORS

DOUBLE HELIX SPONSORS HELIX SPONSOR

CONFERENCE SPONSORS

usedlabequipment.com

MEDIA PARTNERS

TM

#BIOCEO17 11 February 13-14, 2017 • The Waldorf Astoria New York ADVISORY COMMITTEE

John Chambers Barbara J. Dalton, PhD Linda S. Grais, MD Brian Hagerty Nouhad Husseini President and Head of Vice President, Venture President and Chief Senior Director, Head Vice President, Healthcare Investment Capital, Pfizer Inc. Executive Officer, Ocera of Healthcare Capital Business Development, Banking, H.C. Therapeutics, Inc. Markets, New York Regeneron Wainwright & Co. LLC Stock Exchange Pharmaceuticals, Inc.

Mike King Jonathan Leff Michael Margolis, RPh Michael Mirsky Timothy P. O’Connor, PhD Managing Director and Partner, Deerfield Managing Director and Managing Director, Executive Vice President, Senior Biotech Analyst, Management; Head of Healthcare Investment Banking, The Rockefeller University JMP Securities Chairman, Deerfield Investment Banking, H.C. Wainwright & Co., LLC Institute ROTH Capital Partners

Jason Park Susan Peschin, MHS Dennis J. Purcell Carlo Rizzuto, PhD Matthew Roden, PhD Principal, Flagship President and CEO, Founder and Senior Partner, Versant Vice President and Head Ventures Alliance for Aging Advisor, Aisling Capital Ventures of Strategic Corporate Research Development, Bristol- Myers Squibb

Stephen Sands Rajeev Shah Nathan Tinker, PhD Vice Chairman Investment Managing Director and Executive Director, Banking and Chairman Portfolio Manager, New York BIO Global Healthcare Group, RA Capital Management Lazard

12 bio.org/CEO HOSTED BY: